Alogliptin, Alogliptin-metformin, Alogliptin-pioglitazone, Jentadueto[®], Jentadueto[®] XR, Kazano, Kombiglyze XR[®], Nesina, Onglyza[®], Oseni & Tradjenta[®] Prior Authorization Request Form (Page 1 of 2) DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY HAVE BARCODES.

This form may be faxed to 844-403-1029.

Member Information (required)			Provider Information (required)			
Member Name:			Provider Name:			
Insurance ID#:			NPI#: Specialty:			
Date of Birth:			Office Phone:			
Street Address:			Office Fax:			
City:	State:	ZIP:	Office Street Address:			
Phone:			City:	State: ZIP		IP:
Medication Information (required)						
Medication Name:			Strength:	Dosage Form:		n:
			Directions for Use:			
Clinical Information (required)						
 Select the diagnosis below: Type 2 diabetes mellitus (adjunct to diet and exercise) 						
□ Other diagnosis: ICD-10 Code:						_
2. Has the patient demonstrated a failure of or intolerance to a majority (two or more in a class with at least					t 🛛 Yes 🗅 No	
two alternatives or one in a class with only one alternative) of the preferred formulary/preferred drug list alternatives for the given diagnosis (e.g., Januvia, Janumet, Janumet XR)?						
If yes, please submit documentation including medication(s) tried, dates of trial(s) and reason for						
treatment failure(s):						_
3. Does the patient have a documented contraindication to the listed formulary alternatives (e.g., Januvia, Janumet, Janumet XR)?						🗆 Yes 🗅 No
If yes, please submit documentation including medication name(s) and contraindication:						
4. Has the patient had an adverse reaction to OR would be reasonably expected to have an adverse reaction to a majority (two or more in a class with at least two alternatives or one in a class with only one						
alternative) of the listed formulary agents used for the requested indication (e.g., Januvia, Janumet,						
Janumet XR)? If yes, please submit documentation including medication name(s) and adverse reaction(s):						
						-
5. Does the patient have a clinical condition for which there is no listed formulary agent to treat the						🛛 Yes 🖵 No
condition based on published guidelines or clinical literature? If yes, please submit documentation including the clinical condition:						_
6. Is the drug being prescribed within the manufacturer's published dosing guidelines (e.g., package insert)) 🛛 Yes 🖵 No
or does the dose AHFS, Micromed	pted compendia or current literature (e.g.,					
_ ,	,	J / -				

This document - and others if attached - contains information that is privileged, confidential and/or may contain protected health information (PHI). The provider named above is required by applicable law to safeguard PHI. The information in this document is for the sole use of OptumRx. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. If you are not the intended recipient, please notify the sender immediately. Office use only: DPP4Inhibitors_2019Dec

Alogliptin, Alogliptin-metformin, Alogliptin-pioglitazone, Jentadueto[®], Jentadueto[®] XR, Kazano, Kombiglyze XR[®], Nesina, Onglyza[®], Oseni & Tradjenta[®] Prior Authorization Request Form (Page 2 of 2)

Information on this form is accurate as of this date.

Prescriber's Signature:

Date:

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

<u>Please note</u>: **This request may be denied unless all required information is received.** For more information about the prior authorization process, please contact us at 855-811-2218. Monday – Friday: 8 a.m. to 1 a.m. Eastern, and Saturday: 9 a.m. to 6 p.m. Eastern

This document – and others if attached – contains information that is privileged, confidential and/or may contain protected health information (PHI). The provider named above is required by applicable law to safeguard PHI. The information in this document is for the sole use of OptumRx. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. **If you are not the intended recipient, please notify the sender immediately.** Office use only: DPP4Inhibitors_2019Dec